(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 22 July 2014 - Actelion Ltd (SIX: ATLN) today announced its results for the first half of 2014. OPERATING HIGHLIGHTS Opsumit - US launch momentum remains strong Opsumit - Ten market introductions in HY 2014; filed in Japan Selexipag - Phase III GRIPHON study in PAH meets primary endpoint Tracleer - Demand robust in non-Opsumit markets FINANCIAL HIGHLIGHTS Product sales of CHF 993 million, up 17% at Constant Exchange Rates (CER), 11% excluding US rebate reversals Core earnings of CHF 421 million, up 35% at CER, 21% excluding US rebate reversals Core EPS of CHF 3.25, an increase of 48% at CER Upgraded 2014 financial guidance - Core...
↧